Aligos Therapeutics, Inc. (ALGS) vs Neuphoria Therapeutics Inc. (NEUP)

Aligos Therapeutics, Inc. and Neuphoria Therapeutics Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Neuphoria Therapeutics Inc. are of similar size ($14.0M and $14.0M). Neuphoria Therapeutics Inc. grew revenue faster over the last twelve months: 3,535.1% against 1,171.6%. Neuphoria Therapeutics Inc. has the higher net margin (0.00% vs −197.0%) and the lower return on invested capital (−232.7% vs 0.00%). Across the 17 metrics below, Neuphoria Therapeutics Inc. leads on 11 and Aligos Therapeutics, Inc. on 6.

Valuation

Metric ALGS NEUP Biotechnology median
P/E n/m n/m 11.36
P/S 0.66 0.72 9.12
P/B 1.95 0.46 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA 0.13 0.46 0.62
EV/Sales (0.28) (0.49) 8.56
Earnings yield (300.95%) (197.65%) (34.18%)
Free cash flow yield (311.04%) (108.85%) (23.62%)

Profitability

Metric ALGS NEUP Biotechnology median
Gross margin 100.00% 0.00% 67.24%
Operating margin (215.55%) 0.00% 0.00%
Net margin (197.01%) 0.00% 0.00%
Free cash flow margin (204.07%) 0.00% 0.00%
Return on equity (159.46%) (61.70%) (50.28%)
Return on assets (84.46%) (46.95%) (45.89%)
Return on invested capital 0.00% (232.67%) 0.00%

Growth

Metric ALGS NEUP Biotechnology median
Revenue growth (TTM) 1,171.58% 3,535.05% 6.96%
EPS growth (last fiscal year) 88.30% (1,230.43%) 29.86%
Revenue growth, 5-year CAGR — 19.07% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS NEUP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.77 27.85 4.72
Net debt to EBITDA 0.87 1.26 1.01

Dividend

Metric ALGS NEUP Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ALGS NEUP Biotechnology median
Market cap 13.95m 13.96m 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack